Stocks Hesitate After Back-to-Back Winning Weeks
Stocks were little changed Monday as markets cooled off following a winning week as traders awaited key retail earnings and a speech from Federal Reserve Chair Jerome Powell.
The Dow Jones Industrial Average eked up 1.97 points to 44,948.09.
The S&P 500 index sagged 1.49 points to open the day and the week at 6,448.31.
The NASDAQ fell 14.41 points to 21,608.56.
Shares of Novo Nordisk added more than 4% after the company’s Wegovy obesity drug was granted accelerated approval from the U.S. Food and Drug Administration for the treatment of a serious liver disease.
Big-box retailers, including Home Depot, Lowe’s, Walmart and Target, are among the major companies slated to release results this week. Investors will parse through these reports for clues on how the U.S. consumer is doing.
The Fed will also continue to be in focus this week as central bank members travel to Jackson Hole, Wyoming, for the annual economic policy symposium.
Investors will be monitoring the event for clues about the future path of rates. Fed funds futures are pricing in a nearly 85% likelihood that the central bank cuts rates at its next policy meeting in September
Prices for 10-year Treasury lost ground Thursday, raising yields to 4.33% from Friday’s 4.32%. Treasury prices and yields move in opposite directions.
Oil prices dipped 40 cents to $62.40 U.S. a barrel.
Gold prices were static at $3,382.60 U.S. an ounce.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


